<DOC>
	<DOCNO>NCT01186770</DOCNO>
	<brief_summary>MNTX 3201 Phase 3 , international , multicenter , randomize , double-blind , placebo-controlled , parallel-group study order evaluate safety efficacy oral MNTX treatment opioid induce constipation subject chronic , non-malignant pain .</brief_summary>
	<brief_title>A Study Oral Methylnaltrexone ( MNTX ) Treatment Opioid-Induced Constipation Subjects With Chronic , Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>Key 1 . History chronic nonmalignant pain ( originate nonmalignant source ) . 2 . Taking oral , transdermal , intravenous , subcutaneous opioids chronic nonmalignant pain . 3 . No known history chronic constipation prior initiation opioid therapy . 4 . Currently take laxative therapy willing discontinue laxative therapy prestudy use studypermitted rescue laxative . Key 1 . Prior treatment oral methylnaltrexone . 2 . Prior treatment SC methylnaltrexone within 30 day prestudy . 3 . Women pregnant , breastfeeding , plan become pregnant . 4 . Gastrointestinal disorder know affect bowel transit . 5 . Current treatment partial opioid agonist ( e.g. , buprenorphine ) combination agonists/antagonists .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Treatment Opioid-Induced Constipation Subjects Chronic , Non-Malignant Pain</keyword>
</DOC>